Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 1.00 |
| ▸ | NPC1 | O15118 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 3/20 | 1.00 |
| ▸ | RELA | Q04206 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | SCD | O00767 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Frentizole SCHEMBL11433152 | 0.99 | RAB9A (0.98) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL23357 | 0.92 | RAB9A (0.84) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL10812423 | 0.90 | NPC1 (0.82) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL210774 | 0.90 | RAB9A (0.81) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL4924519 | 0.88 | RAB9A (0.79) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL4918017 | 0.88 | RAB9A (0.79) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL11725983 | 0.88 | RAB9A (0.79) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL4909989 | 0.88 | RAB9A (0.78) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL6231579 | 0.87 | MAPT (1.00) | RAB9ANPC1KMT2AMEN1MAPT | |
| SCHEMBL11724340 | 0.87 | KMT2A (0.77) | RAB9ANPC1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-10-10 | — | — | US | claimed |
| EP-4380557-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | National University of Singapore (SG) | 2024-06-12 | — | — | EP | claimed |
| WO-2023014296-A2 | MOLECULAR GLUE AND SALL4 DEGRADER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-02-09 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1363625-A4 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX INC (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-1363625-A1 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | Combinatorx, Incorporated (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | ZALICUS INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002058697-A1 | COMBINATIONS OF DRUGS (E.G., A BENZIMIDAZOLE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2002-08-01 | — | — | WO | claimed |
| US-20250101026-A1 | Functionalized Allopurinol Derivatives for Treatment of Alzheimer’s Disease | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2025-03-27 | — | — | US | disclosed |
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-10-10 | — | — | US | disclosed |
| US-4153709-A | BENZIMIDAZOLES OR NAPHTHIMIDAZOLES | ELI LILLY AND COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
| US-4088768-A | BENZIMIDAZOLYL, BENZOTHIAZOLYL, AND BENZOXAZOLYL UREAS AND THIOUREAS | ELI LILLY AND COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4046770-A | IMMUNE REGULANTS | ELI LILLY AND COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335429-A1 | MOLECULAR GLUE AND SALL4 DEGRADER | SALL4, SAV1, SUMO1 | RAB9A 2386/4885NPC1 3795/4885KMT2A 972/4885 |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | RAB9A 3792/4885NPC1 1713/4885KMT2A 1419/4885 |
| US-20020165261-A1 | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders | DHFR, DPYD, VHL | RAB9A 3865/4885NPC1 2404/4885KMT2A 1930/4885 |
| US-20250101026-A1 | Functionalized Allopurinol Derivatives for Treatment of Alzheimer’s Disease | XDH, UGDH, SMN1; SMN2 | RAB9A 3516/4885NPC1 2040/4885KMT2A 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.